Loading…
← CockpitCompetitor Analysis › 9987.T Suzuken Co., Ltd.Open in the cockpit ↗

Suzuken Co., Ltd.9987.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors

One of Japan's largest pharmaceutical wholesalers, distributing drugs and medical devices to hospitals and pharmacies.

≈ Japan's AmerisourceBergenMomentum leader 84
Mkt cap
$2.36B
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$8.08M
20-day average traded
Fwd P/E
15.8×
forward earnings
ROIC−WACC
+2.8 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · JPY¥2,878
1D-1.0%
1W+2.8%
1M+3.7%
3M+15.1%
6M+8.4%
YTD-6.1%
1Y-0.2%
ATR %3.0%
52w lowhigh13.7% off high

What Suzuken does

One of Japan's largest pharmaceutical wholesalers, distributing drugs and medical devices to hospitals and pharmacies.

Buys drugs from manufacturers and resells them to hospitals and pharmacies for a thin margin, so income depends on volume and on the government-set drug price list, which is revised regularly, usually downward. One of four nationwide wholesalers that dominate Japan's drug distribution, alongside Medipal, Alfresa and Toho.

In one line: Japan's AmerisourceBergen.

Products and services

  • Pharmaceutical wholesale distribution
  • Medical device distribution
  • Home healthcare products

Customers

  • Hospitals
  • Pharmacies
  • Clinics

Where it sits in the supply chain

  • Health care
  • Pharmaceutical distribution
  • Wholesale distribution of drugs and…

What could go right

  • Drug volume growth from aging population

What could go wrong

  • Thin distribution margins
  • Drug price revisions by government

Moat: narrow (scale, distribution, regulatory licence). Nationwide licensed distribution network and scale purchasing in a low-margin, logistics-heavy business.

Headquarters: Nagoya, Japan · Founded: 1946 · Employees: 12,717

Named competitors

Suzuken at a glance

Size Suzuken (9987.T) is a Japan Health Care company (Medical Distributors) with a market value of $2.36B, the 441st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,878 on 18 Nov 2026.

Performance Over six months the shares gained 8.4%, against +7.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 5.2% over the last twelve months (peer median +6.3%); the operating margin is 1.3% (peer median 3.6%).

Valuation It trades at 15.8× forward earnings against a peer median of 18.4× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20269987.T 109Peer median 109
Six months, rebased to 100: Suzuken against the median of its 20 peers (local-currency closes).

Suzuken financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥2.55T¥2.49T¥2.40T¥2.39T¥2.31T
Revenue growth—+4%+1%+3%—
Gross profit¥192B¥193B¥192B¥185B¥180B
EBITDA¥45.8B¥48.7B¥49.2B¥43.6B¥41.5B
Net income¥34.9B¥38.1B¥34.5B¥29.0B¥20.3B
Free cash flown/a¥18.5B-¥79.4B¥76.4B¥22.2B
Capital expendituren/a¥17.8B¥18.6B¥15.6B¥17.7B
Total debt¥23.5B¥1.78B¥1.80B¥1.80B¥1.80B

Quarterly statements and history in the cockpit →

Suzuken competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+20%008930ASKER27843349AMP7459RDC60099833606005877476DOCM301584GALE600713603368ARJO-BDKSHENTERO9987.T6-month return →1-month return →
Up and to the right = strong over both horizons. Suzuken is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×ASKER27843349AMP812974596009986005877476GALE603368ARJO-BDKSHENTERO9987.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Suzuken is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%008930ASKER2784AMP812974596009983360301584GALEDKSHENTERO9987.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Suzuken is the large dot.

Suzuken competitors and peer comparison

Head to head with its named competitors (9987.T vs 7459.T vs 2784.T vs 8129.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Suzuken 9987.T$2.36B+8%+5%1%15.8×-10.4%
MEDIPAL 7459.T$3.70B+15%+4%1%12.5×-7.2%
Alfresa 2784.T$2.81B-3%+4%1%18.4×-8.4%
Toho 8129.T$1.64B-5%+4%1%22.2×-4.6%

How Suzuken compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Suzuken against its 20 peers (data as of 18 Nov 2026)
Measure9987.TPeer medianRank in peer set
1-month return+3.7%+1.8%9th highest of 21
6-month return+8.4%+7.9%10th highest of 21
Distance from 52-week high-13.7%-14.3%10th highest of 21
Revenue growth (TTM)+5.2%+6.3%9th lowest of 21
Operating margin1.3%3.6%5th lowest of 21
Forward P/E15.8×18.4×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)-10.4%-1.1%2nd least demanding of 17
Growth delivered (Del g)+3.2%+6.1%3rd lowest of 17
Hurdle (Req g minus delivered)-13.6 pp-7.8 pp4th least demanding of 17
ROIC minus cost of capital+2.8 pp+1.6 pp6th highest of 21
Net debt / EBITDA-2.7×0.9×3rd least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%23.9×7.0%+3.5%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%21.8×-1.2%+0.6%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%

Questions

Who are Suzuken's main competitors?
Named competitors: Medipal Holdings (7459.T), Alfresa Holdings (2784.T), Toho Holdings (8129.T). The cockpit's measured peer set (industry) also includes Hanmi Science (008930.KS), Asker Healthcare (ASKER.ST), Alfresa (2784.T), COSMOS Pharmaceutical (3349.T), Amplifon (AMP.MI), Toho (8129.T).
Is Suzuken expensive compared with its peers?
On forward p/e it trades at 15.8× against a peer median of 18.4×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Suzuken stock performed?
Over six months to 18 Nov 2026 the shares returned +8.4% against +7.9% for the median peer; over one year -0.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.